Congenital adrenal hyperplasia: Difference between revisions

Jump to navigation Jump to search
No edit summary
(Undo revision 1465293 by Mehrian.jafari (talk))
 
(129 intermediate revisions by 6 users not shown)
Line 1: Line 1:
'''This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on 21-hydroxylase deficiency, 17a-Hydroxylase deficiency, 11β-hydroxylase deficiency, 3-beta-hydroxysteroid dehydrogenase, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia, cholesterol side-chain cleavage enzyme deficiency'''
 
.
'''This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on [[21-hydroxylase deficiency]], [[17 alpha-hydroxylase deficiency]], [[11β-hydroxylase deficiency]], [[3 beta-hydroxysteroid dehydrogenase deficiency]], [[cytochrome P450-oxidoreductase (POR) deficiency (ORD)]], [[congenital lipoid adrenal hyperplasia]]'''.


<div style="-webkit-user-select: none;">
<div style="-webkit-user-select: none;">
__NOTOC__
__NOTOC__
{{Infobox Disease
| Name = Adrenal insufficiency
| Image = Illu adrenal gland.jpg
| Caption = Adrenal gland
}}
{{Congenital adrenal hyperplasia}}
{{Congenital adrenal hyperplasia}}


{{CMG}}; {{AE}}{{MJ}}
{{CMG}}; {{AE}}{{MJ}}


{{SK}} Congenital adrenal hyperplasia, CAH, Adrenal hyperplasia
{{SK}} Congenital adrenal hyperplasia; CAH; Adrenal hyperplasia.


==Overview==
==Overview==
Congenital adrenal hyperplasia consists of several disorders resulting from defective [[enzymes]] and [[proteins]] involved in [[steroid]] and [[cortisol]] synthesis pathways. Defects in [[steroid]] [[biosynthesis]] are caused by several [[genetic mutations]] and may lead to [[delayed puberty]], [[precocious puberty]] or [[ambiguous genitalia]] in specific disorders. The decrease in [[cortisol]] level leads to the release of the inhibitory feedback on [[corticotropin]] ([[ACTH]]) production. The high [[ACTH]] level causes increase [[cortisol]] precursors and overproduction of other [[hormones]]. The most common cause of congenital adrenal hyperplasia is a [[21-hydroxylase deficiency]], which accounts for more than 95% of cases. Other causes include [[17 alpha-hydroxylase deficiency]], [[11β-hydroxylase deficiency]], [[3 beta-hydroxysteroid dehydrogenase deficiency]], [[Cytochrome P450-oxidoreductase (POR) deficiency (ORD)]], and [[congenital lipoid adrenal hyperplasia]].


==Classification==
==Classification==
Congenital adrenal hyperplasia is classified into seven types based on the genetic causes that lead to hyperplasia and hormonal imbalance.
Congenital adrenal hyperplasia (CAH) is classified into seven types based on the [[genetic]] causes that lead to [[hyperplasia]] and [[Hormone|hormonal]] imbalance. CAH is [[hyperplasia]] of different layer of [[Adrenal cortex]]. Within the [[adrenal cortex]], there are three layers named zones; each of them has a distinct cell type and secrete specific [[hormones]].
==== [[Adrenal cortex]] zones based on the hormonal synthesis ability and location: ====
<div style="-webkit-user-select: none;">
* Zona glumerulosa:
** The outer layer of [[adrenal cortex|adrenal cortex.]]
** Laying directly under the [[Adrenal gland|adrenal]] [[capsule]].
** Secretion: [[Aldosterone]] synthesis.
* Zona fasciculate:
** The middle part of [[adrenal cortex]]
** Laying under zona glumerulosa
** Secretion: [[Cortisol]] synthesis
* Zona reticularis:
** The inner part of [[adrenal cortex]]
** Laying between zona fasciculate and [[adrenal medulla]]
** Secretion: [[Androgen]] synthesis
 
[[image:Adrenal cortex labelled.jpg|600px|center|thumb|[[Adrenal cortex]] zones -  By Jpogi - https://commons.wikimedia.org/wiki/File:Adrenal_gland_%28cortex%29.JPG, CC0, https://commons.wikimedia.org/w/index.php?curid=37838551]]
 
==== Impairment of each pathway and [[enzyme]] may lead to a specific subtype of congenital adrenal hyperplasia include: ====
<div style="-webkit-user-select: none;">
* [[21-hydroxylase deficiency]]
* [[17 alpha-hydroxylase deficiency]]
* [[11β-hydroxylase deficiency]]
* [[3 beta-hydroxysteroid dehydrogenase deficiency]]
* [[Cytochrome P450-oxidoreductase (POR) deficiency (ORD)]]
* [[Congenital lipoid adrenal hyperplasia]]
 
====Adrenal steroid synthesis pathways in adrenal cortex and related enzymes====
 
[[image:Adrenal Steroids.png|thumb|800px|center|Adrenal steroid synthesis pathways in adrenal cortex and related enzymes <ref name="urlFile:Adrenal Steroids Pathways.svg - Wikimedia Commons">{{cite web |url=https://commons.wikimedia.org/wiki/File:Adrenal_Steroids_Pathways.svg|title=File:Adrenal Steroids Pathways.svg - Wikimedia Commons |format= |work= |accessdate=}}</ref>]]
 
==== Summary and important Characteristics of the different congenital adrenal hyperplasia subtypes: <ref name="pmid2164530">{{cite journal |vauthors=Moreira AC, Leal AM, Castro M |title=Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency |journal=J. Clin. Endocrinol. Metab. |volume=71 |issue=1 |pages=86–91 |year=1990 |pmid=2164530 |doi=10.1210/jcem-71-1-86 |url=}}</ref><ref name="pmid999330">{{cite journal |vauthors=Heremans GF, Moolenaar AJ, van Gelderen HH |title=Female phenotype in a male child due to 17-alpha-hydroxylase deficiency |journal=Arch. Dis. Child. |volume=51 |issue=9 |pages=721–3 |year=1976 |pmid=999330 |pmc=1546244 |doi= |url=}}</ref><ref name="pmid226795">{{cite journal |vauthors=Biglieri EG |title=Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome |journal=J. Steroid Biochem. |volume=11 |issue=1B |pages=653–7 |year=1979 |pmid=226795 |doi= |url=}}</ref>====
<div style="-webkit-user-select: none;">
{| class="wikitable" align="center" style="border: 0px; font-size: 90%; margin: 3px;"
! colspan="2" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History and symptoms
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory findings
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Defective gene
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Blood pressure
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Genitalia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Cortisol
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Aldosterone
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Androgens
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Estrogens
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Increased hormone precursors
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Potassium levels
|-
| rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[21-hydroxylase deficiency]]
| style="background:#DCDCDC;" |Classic type, salt-wasting
| align="center" style="padding: 5px 5px; background: " |↓
|
* Female: [[Ambiguous genitalia]]
 
* Male: Normal or scrotal [[pigmentation]] and large phallus 
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓↓
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |Relatively low
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
| align="center" style="padding: 5px 5px; background: " |↑
|
[[CYP21A1]] and [[CYP21A2]] gene
|-
| style="background:#DCDCDC;" |Classic type, non-salt-wasting
| align="center" style="padding: 5px 5px; background: " |Normal
|
* Female: [[Ambiguous genitalia]]
 
* Male: normal or scrotal pigmentation and large phallus
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |Relatively low
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
| align="center" style="padding: 5px 5px; background: " |Normal
|[[CYP21A1]] and [[CYP21A2]] gene
|-
| style="background:#DCDCDC;" |Non-classic type
| align="center" style="padding: 5px 5px; background: " |Normal
|
* Female: [[Virilization]] after [[puberty]]
* Male: Normal appearance
| align="center" style="padding: 5px 5px; background: " |Normal
| align="center" style="padding: 5px 5px; background: " |Normal
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |Relatively low
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] response to [[ACTH]]
| align="center" style="padding: 5px 5px; background: " |Normal
|
[[CYP21A1]] and [[CYP21A2]] gene
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: " |↑
|
* Female: Normal
* Male: [[Ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: " |Normal [[corticosterone]]
Normal [[cortisol]]
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
|
* [[Deoxycorticosterone]]
* [[Progesterone]]
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |[[CYP17A1]]
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: " |↑
|
* Female: [[Ambiguous genitalia]]
 
* Male: Normal or scrotal pigmentation and large [[Phallus (embryology)|phallus]]
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |Relatively low
|
* [[Deoxycorticosterone]]
* 11-Deoxy-[[cortisol]]
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]], mild elevation
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |CYP11B1
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[3 beta-hydroxysteroid dehydrogenase deficiency]]
| align="center" style="padding: 5px 5px; background: " |↓
|
* Both male and female: [[Ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |Male:↓
Female:↑
| align="center" style="padding: 5px 5px; background: " |↓
|
* [[Dehydroepiandrosterone]]
* [[17-hydroxypregnenolone]]
* [[Pregnenolone]]
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |HSD3B2
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Cytochrome P450-oxidoreductase (POR) deficiency (ORD)]]
| align="center" style="padding: 5px 5px; background: " |Normal
|
* Both male and female: [[Ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: " |↓
 
| align="center" style="padding: 5px 5px; background: " |Normal
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
|
* [[Dehydroepiandrosterone]]
* [[17-hydroxypregnenolone]]
* [[Pregnenolone]]
| align="center" style="padding: 5px 5px; background: " |Normal
|[[Mutations]] in the [[flavoprotein]] co-factor of the enzymes [[CYP17A1]], [[CYP21A2]], and [[CYP19A1]] ([[aromatase]]).
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Congenital lipoid adrenal hyperplasia]]
| align="center" style="padding: 5px 5px; background: " |↓
|
* Female: Normal, [[delayed puberty]] in females
* Male: [[Ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |None of precursors increased
| align="center" style="padding: 5px 5px; background: " |↓
|[[Gene mutation|Gene mutations]] on [[Chromosome 8 (human)|chromosome 8]], codes for a [[protein]] called [[steroid]] acute regulatory protein (StAR)
|}
 
==Differential Diagnosis==
Congenital adrenal hyperplasia can present with different symptoms such as:
* [[Ambiguous genitalia]]
* [[Virilization]] and [[hirsutism]] in female
* [[Primary amenorrhea]]
* Low reninemic [[hypertension]]
Differential diagnosis for each of these symptoms are described in below tables.
 
===[[Congenital adrenal hyperplasia]] must be differentiated from diseases that cause [[ambiguous genitalia]]:<ref name="pmid17875484">{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=21 |issue=3 |pages=351–65 |year=2007 |pmid=17875484 |doi=10.1016/j.beem.2007.06.003 |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref>===


{| align="center" class="wikitable" style="border: 0px; font-size: 90%; margin: 3px;"
{| class="wikitable"
! align="center" style="background:#DCDCDC;" |Disease
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease  
! align="center" style="background:#DCDCDC;" colspan="5" |History and symptoms
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Steroid status
! align="center" style="background:#DCDCDC;" colspan="8" |Laboratory findings
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings
! align="center" style="background:#DCDCDC;" |Additional findings
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" |21-hydroxylase deficiency
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Increased
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Decreased
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
|-
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
|[[21-hydroxylase deficiency|Classic type of 21-hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
* [[Progesterone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''''↑'''''
* [[Androstenedione]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
* [[DHEA]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |N/'''↑'''
* [[Aldosterone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
* [[Corticosterone]] (salt-wasting)
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↓'''
* [[Cortisol]] ([[virilization]])
!Normal
|
|
* [[Ambiguous genitalia]] in female
* [[Virilization]] in female
* Salt-wasting
* [[Hypotension]] and [[hyperkalemia]]
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" |17a-Hydroxylase deficiency
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
* [[Deoxycorticosterone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
* 11-Deoxy-[[cortisol]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] (mild elevation)
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
* [[Cortisol]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
* [[Corticosterone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
* [[Aldosterone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
* [[Ambiguous genitalia]] in female
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
* [[Hypertension]] and [[hypokalemia]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
* [[Virilization]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
|-
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |[[Acanthosis nigricans]]
|[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]]
|
* [[Deoxycorticosterone]]
* [[Corticosterone]]
* [[Progesterone]]
|
* [[Cortisol]]
* [[Aldosterone]]
|
* [[Ambiguous genitalia]] in male
* [[Hypertension]]
 
* [[Primary amenorrhea]]
 
* Absence of [[secondary sexual characteristics]]
 
* Minimal [[body hair]]
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" |11β-hydroxylase deficiency
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
* [[Dehydroepiandrosterone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
* [[17-hydroxypregnenolone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* [[Pregnenolone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
* [[Cortisol]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
* [[Aldosterone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
* [[Vomiting]], [[volume depletion]], [[hyponatremia]], and [[hyperkalemia]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
* 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |N
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" |3-beta-hydroxysteroid dehydrogenase
| Gestational [[hyperandrogenism]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
| colspan="2" |
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* If [[virilization]] is caused by exogenous [[hormone]] administration, the values may be low because the offending hormone is usually a synthetic [[steroid]] not measured in assays for [[testosterone]] or other [[androgens]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* [[Androgen]] excess in mother
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
* History of [[androgen]] containing [[medication]]  consumption during [[pregnancy]] in mother
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
* [[Virilization]] in a 46,XX individual with normal female internal anatomy
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
* Causes include maternal [[luteoma]] or theca-[[lutein]] [[cysts]], and [[placental]] [[aromatase]] enzyme deficiency
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↓'''
|}
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
 
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
===Congenital adrenal hyperplasia must be differentiated from diseases that cause [[virilization]] and [[hirsutism]] in female:<ref name="pmid24830586">{{cite journal |vauthors=Hohl A, Ronsoni MF, Oliveira Md |title=Hirsutism: diagnosis and treatment |journal=Arq Bras Endocrinol Metabol |volume=58 |issue=2 |pages=97–107 |year=2014 |pmid=24830586 |doi= |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref><ref name="ISBN:978-0323297387">{{cite book | last = Melmed | first = Shlomo | title = Williams textbook of endocrinology | publisher = Elsevier | location = Philadelphia, PA | year = 2016 | isbn = 978-0323297387 }}=</ref>===
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
 
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
{| class="wikitable"
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Steroid status
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other laboratory
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" |Cytochrome P450-oxidoreductase (POR) deficiency (ORD)
|Non-classic type of [[21-hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
|Increased:
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] in response to [[ACTH]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* Low [[testosterone]] levels
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
* No symptoms in infancy and male
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
 
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
* [[Virilization]] in females
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
|-
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
|Increased:
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
* DOC
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* 11-Deoxy-[[Cortisol]]
Decreased:
* [[Cortisol]]
* [[Corticosterone]]
* [[Aldosterone]]
|
* Low [[testosterone]] levels
|
* [[Hypertension]] and [[hypokalemia]]
* [[Virilization]]
|-
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
|Increased:
* [[DHEA]]
* [[17-hydroxypregnenolone]]
* [[Pregnenolone]]
Decreased:
* [[Cortisol]]
* [[Aldosterone]]
|
* Low [[testosterone]] levels
|
* Salt-wasting [[adrenal crisis]] in infancy
 
* Mild [[virilization]] of genetically female infants
* [[Undervirilization]] of genetically male infants, making it the only form of [[CAH]] which can cause [[ambiguous genitalia]] in both genetic sexes.
|-
|[[Polycystic ovary syndrome ]]
|
* High [[DHEAS]] and [[androstenedione]] levels
|
* Low [[testosterone]] levels
|
* [[Polycystic ovaries]] in sonography
* [[Obesity]]
* [[PCOS]] is the most common cause of [[hirsutism]] in women
* No evidence another diagnosis
|-
|[[Adrenal tumors]]
|
* Variable levels depends on [[tumor]] type
|
* Low [[testosterone]] level
|
* Older age
* Rapidly progressive symptoms
|-
|Ovarian [[virilizing]] tumor
|
* Variable levels depends on [[tumor]] type
|
* [[Testosterone]] is high
|
* Older age
* Rapidly progressive symptoms
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" |Congenital lipoid adrenal hyperplasia
|[[Cushing's syndrome]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* Increase [[cortisol]] & metabolites
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* Variable other [[steroids]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* Variable [[mineralocorticoid]] excess
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
* [[Cushingoid appearance]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |N/'''↑'''
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |In hospitalized patients especially in [[ICU]] and [[CCU]]
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" |Cholesterol side-chain cleavage enzyme deficiency
|[[Hyperprolactinemia]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* Normal levels of most of [[steroids]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | -
* Increased [[prolactin]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | +
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
* [[Infertility]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
* [[galactorrhea]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |Normal
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''↑'''
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |N/'''↑'''
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |N/'''↑'''
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |[[Acanthosis nigricans|Acanthosis nigricans,]]  
|}
|}


==Complications==
===Some types of congenital adrenal hyperplasia must be differentiated from diseases with [[primary amenorrhea]]:<ref name="pmid21147889">{{cite journal |vauthors=Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C |title=Phenotypical, biological, and molecular heterogeneity of -reductase deficiency: an extensive international experience of 55 patients |journal=J. Clin. Endocrinol. Metab. |volume=96 |issue=2 |pages=296–307 |year=2011 |pmid=21147889 |doi=10.1210/jc.2010-1024 |url=}}</ref><ref name="pmid2164530">{{cite journal |vauthors=Moreira AC, Leal AM, Castro M |title=Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency |journal=J. Clin. Endocrinol. Metab. |volume=71 |issue=1 |pages=86–91 |year=1990 |pmid=2164530 |doi=10.1210/jcem-71-1-86 |url=}}</ref><ref name="pmid999330">{{cite journal |vauthors=Heremans GF, Moolenaar AJ, van Gelderen HH |title=Female phenotype in a male child due to 17-alpha-hydroxylase deficiency |journal=Arch. Dis. Child. |volume=51 |issue=9 |pages=721–3 |year=1976 |pmid=999330 |pmc=1546244 |doi= |url=}}</ref><ref name="pmid226795">{{cite journal |vauthors=Biglieri EG |title=Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome |journal=J. Steroid Biochem. |volume=11 |issue=1B |pages=653–7 |year=1979 |pmid=226795 |doi= |url=}}</ref><ref name="pmid8929268">{{cite journal |vauthors=Saenger P |title=Turner's syndrome |journal=N. Engl. J. Med. |volume=335 |issue=23 |pages=1749–54 |year=1996 |pmid=8929268 |doi=10.1056/NEJM199612053352307 |url=}}</ref><ref name="pmid25813279">{{cite journal |vauthors=Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R |title=Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis |journal=Fertil. Steril. |volume=103 |issue=5 |pages=1297–304 |year=2015 |pmid=25813279 |doi=10.1016/j.fertnstert.2015.01.043 |url=}}</ref><ref name="pmid4432067">{{cite journal |vauthors=Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE |title=Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism |journal=Science |volume=186 |issue=4170 |pages=1213–5 |year=1974 |pmid=4432067 |doi= |url=}}</ref><ref name="pmid11344932">{{cite journal |vauthors=Schnitzer JJ, Donahoe PK |title=Surgical treatment of congenital adrenal hyperplasia |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=1 |pages=137–54 |year=2001 |pmid=11344932 |doi= |url=}}</ref>===
Complications of diabetes mellitus may be classified as [[Acute (medicine)|acute]] or [[Chronic (medical)|chronic]]. Acute complications of diabetes mellitus may occur in [[Diabetes mellitus type 1|type 1]], [[Diabetes mellitus type 2|type 2]], or [[gestational diabetes]]. Chronic complications of diabetes mellitus are more likely to occur in long standing [[Diabetes mellitus type 1|type 1]] or [[Diabetes mellitus type 2|type 2]] diabetes and may be further classified as [[Macrovascular disease|macrovascular,]] [[Microvascular disease|microvascular]], or other (unspecified etiology) as follows:<ref name="pmid21366474">{{cite journal |vauthors=Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J |title=Diabetes mellitus, fasting glucose, and risk of cause-specific death |journal=N. Engl. J. Med. |volume=364 |issue=9 |pages=829–41 |year=2011 |pmid=21366474 |pmc=4109980 |doi=10.1056/NEJMoa1008862 |url=}}</ref><ref name="pmid17563022">{{cite journal |vauthors=Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W |title=Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease |journal=Arch. Intern. Med. |volume=167 |issue=11 |pages=1145–51 |year=2007 |pmid=17563022 |doi=10.1001/archinte.167.11.1145 |url=}}</ref><ref name="pmid25562264">{{cite journal |vauthors=Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, Leese G, Leslie P, McCrimmon RJ, Metcalfe W, McKnight JA, Morris AD, Pearson DW, Petrie JR, Philip S, Sattar NA, Traynor JP, Colhoun HM |title=Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010 |journal=JAMA |volume=313 |issue=1 |pages=37–44 |year=2015 |pmid=25562264 |pmc=4426486 |doi=10.1001/jama.2014.16425 |url=}}</ref>


===Acute complications===
{| class="wikitable"
|-
They include [[diabetic ketoacidosis]] (DKA) and [[Hyperosmolar hyperglycemic state]] (HHS). DKA could be the presenting feature of type 1 diabetes and it is more common in type 1 diabetes although, it is sometimes seen in type 2 diabetic patients. [[Hyperosmolar hyperglycemic state|HHS]] is mostly seen in the elderly and it is more common in type 2 diabetes.
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + | Disease
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + | Cause
===Chronic complications===
! colspan="7" style="background:#4479BA; color: #FFFFFF;" + | Differentiating
|-
====Macrovascular====
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Findings
*[[Coronary heart disease]]<ref name="pmid18997199">{{cite journal |vauthors=Nicolucci A |title=Aspirin for primary prevention of cardiovascular events in diabetes: still an open question |journal=JAMA |volume=300 |issue=18 |pages=2180–1 |year=2008 |pmid=18997199 |doi=10.1001/jama.2008.625 |url=}}</ref>
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Uterus
*[[Peripheral arterial disease]]<ref name="pmid27979887">{{cite journal |vauthors= |title=Standards of Medical Care in Diabetes-2017: Summary of Revisions |journal=Diabetes Care |volume=40 |issue=Suppl 1 |pages=S4–S5 |year=2017 |pmid=27979887 |doi=10.2337/dc17-S003 |url=}}</ref>
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Breast development
*[[Cerebrovascular disease]]<ref name="pmid27979887">{{cite journal |vauthors= |title=Standards of Medical Care in Diabetes-2017: Summary of Revisions |journal=Diabetes Care |volume=40 |issue=Suppl 1 |pages=S4–S5 |year=2017 |pmid=27979887 |doi=10.2337/dc17-S003 |url=}}</ref>
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Testosterone
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LH
! align="center" style="background:#4479BA; color: #FFFFFF;" + |FSH
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Karyotyping
|-
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
|
* HSD3B2  [[gene]] [[mutation]]
|
* [[Undervirilization]] in 46,XY individuals due to a block in [[testosterone]] biosynthesis.
* Mild [[virilization]] in 46,XX individuals
| align="center" style="padding: 5px 5px; background: " |
Yes in [[female]]
| align="center" style="padding: 5px 5px; background: " |
Yes in [[female]]
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]] and [[XX]]
|-
|[[17-alpha-hydroxylase deficiency]]
|
* [[CYP17A1|CYP17A1 gene mutation]]
|
* Female [[external genitalia]]


===='''Microvascular'''====
* [[Primary amenorrhea]]
=====Ophthalmic=====
* [[Hypertension]]
*[[Retinopathy]] (nonproliferative/proliferative)<ref name="pmid27979887">{{cite journal |vauthors= |title=Standards of Medical Care in Diabetes-2017: Summary of Revisions |journal=Diabetes Care |volume=40 |issue=Suppl 1 |pages=S4–S5 |year=2017 |pmid=27979887 |doi=10.2337/dc17-S003 |url=}}</ref>
* Absence of secondary [[sexual characteristics]]
*[[Macular edema]]<ref name="pmid27979887">{{cite journal |vauthors= |title=Standards of Medical Care in Diabetes-2017: Summary of Revisions |journal=Diabetes Care |volume=40 |issue=Suppl 1 |pages=S4–S5 |year=2017 |pmid=27979887 |doi=10.2337/dc17-S003 |url=}}</ref>
* Minimal [[body hair]]
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[Gonadal dysgenesis]]
|
* Mutations in [[SRY]], FOG2/ZFPM2, and WNT1
|
* Female [[external genitalia]]
* Intact [[Mullerian ducts]]
* Streak [[gonads]]
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[Testicular regression syndrome]]
|
* Loss of [[testicular]] function and tissue early in development
|
* Female phenotype with atrophic [[Mullerian ducts]].
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[LH receptor|LH receptor defects]]
|
* [[LH receptor]] [[gene]] [[mutation]] on [[chromosome 2]]
|
* Female [[external genitalia]]
* Lack a [[uterus]] and [[fallopian tubes]]
* [[Epididymis]] and [[vas deferens]] may be present
* Laboratory:
** Unresponsiveness to [[hCG]]
** Normal levels of [[testosterone]] precursors (produced in the [[adrenal glands]]).
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[5-alpha-reductase deficiency|5-alpha-reductase type 2 deficiency]]
|
* [[Autosomal recessive]]
|
* Female [[external genitalia or ambiguous]]
* Bilateral testes and normal [[testosterone]] formation


=====Neuropathy=====
* Impaired external [[virilization]] during [[embryogenesis]]
*[[Sensory neuropathy|Sensory]] and [[Motor neuron disease|motor]] (mono- and polyneuropathy)<ref name="pmid27979887">{{cite journal |vauthors= |title=Standards of Medical Care in Diabetes-2017: Summary of Revisions |journal=Diabetes Care |volume=40 |issue=Suppl 1 |pages=S4–S5 |year=2017 |pmid=27979887 |doi=10.2337/dc17-S003 |url=}}</ref>
* Defective conversion of [[testosterone]] to [[DHT]].
*[[Autonomic neuropathy]]<ref name="pmid27979887">{{cite journal |vauthors= |title=Standards of Medical Care in Diabetes-2017: Summary of Revisions |journal=Diabetes Care |volume=40 |issue=Suppl 1 |pages=S4–S5 |year=2017 |pmid=27979887 |doi=10.2337/dc17-S003 |url=}}</ref>
* [[Testosterone]]:[[DHT]] ratio is >10:1
=====Nephropathy=====
| align="center" style="padding: 5px 5px; background: " |
*[[Albuminuria]] and declining [[renal function]]<ref name="pmid27979887">{{cite journal |vauthors= |title=Standards of Medical Care in Diabetes-2017: Summary of Revisions |journal=Diabetes Care |volume=40 |issue=Suppl 1 |pages=S4–S5 |year=2017 |pmid=27979887 |doi=10.2337/dc17-S003 |url=}}</ref>
No
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
Normal male range
| align="center" style="padding: 5px 5px; background: " |
High to normal
| align="center" style="padding: 5px 5px; background: " |
High to normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[Androgen insensitivity syndrome]] 
|
* [[Androgen receptor]] defect
|
* Female [[external genitalia]]
* Resistant to [[testosterone]]
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal male range
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[Mullerian agenesis]]
|
* Mutations in ''[[WNT4]]''
|
* Normal female [[genitalia]]
* Normal [[breast]] development
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal [[female]] range
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XX]]
|-
|[[Ovarian insufficiency|Primary ovarian insufficiency]]
|
* [[Genetic defects]] such as [[turner syndrome]], [[fragile X syndrome]], some other chromosomal defects
|
* Normal [[female genitalia]]
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal female range
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XX]]
|-
|[[Hypogonadotropic hypogonadism]]
|
* Functional, sellar masses
|
* Normal [[female genitalia]],


===Other organs<ref name="pmid27979887">{{cite journal |vauthors= |title=Standards of Medical Care in Diabetes-2017: Summary of Revisions |journal=Diabetes Care |volume=40 |issue=Suppl 1 |pages=S4–S5 |year=2017 |pmid=27979887 |doi=10.2337/dc17-S003 |url=}}</ref>===
* Delayed [[puberty]]
*Gastrointestinal ([[gastroparesis]], [[diarrhea]])
| align="center" style="padding: 5px 5px; background: " |
*Genitourinary ([[uropathy]]/[[sexual dysfunction]])
Yes
*[[List of skin diseases|Dermatologic]]
| align="center" style="padding: 5px 5px; background: " |
*Infectious
No
*[[Cataract|Cataracts]]
| align="center" style="padding: 5px 5px; background: " |
*[[Glaucoma]]
Normal female range
*[[Periodontal disease]]
| align="center" style="padding: 5px 5px; background: " |
*[[Hearing loss]]
Low
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XX]]
|-
| align="center" style="padding: 5px 5px; background: " |
[[Turner syndrome]]
|
* Chromosomal
|
* Normal female [[external genitalia]]
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal [[female]] range
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[Turner syndrome|45 XO]]
|}


Complications of gestational diabetes differs from type 1 and type 2 diabetes primarily due to its pregnancy-specific effects on the mother as well as its effects on the fetus.
=== [[17 alpha-hydroxylase deficiency]] and [[11β-hydroxylase deficiency]] can cause low reninemic [[hypertension]] and should be differentiate from other causes of [[pseudohyperaldosteronism]] (low renin): ===
{| class="wikitable"
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Pseudohyperaldosteronism causes
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical features
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Labratory
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Treatment
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Elevated mineralocorticoid
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Renin
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Aldosterone
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
|-
| rowspan="9" |Endogenous causes
|[[17 alpha-hydroxylase deficiency]]
|Mutations in the [[CYP17A1]] gene
|
* [[Ambiguous genitalia]] in male
* [[Hypertension]]


'''For more information on maternal complications of gestational diabetes [[Gestational diabetes maternal complications|click here]].'''
* [[Primary amenorrhea]]


'''For more information on fetal complications of gestational diabetes [[Gestational diabetes fetal complications|click here]].'''
* Absence of [[secondary sexual characteristics]]


==Screening==
* Minimal [[body hair]]
===Diabetes mellitus type 1===
| rowspan="2" |[[Deoxycorticosterone]] ([[Deoxycorticosterone|DOC]])
According to the American Diabetic Association, screening for type 1 DM is not recommended.
| rowspan="2" |
===Diabetes mellitus type 2===
| rowspan="2" |
Diabetes screening is recommended for many people at various stages of life, and for those with any of several risk factors. American Diabetes Association Recommendations for Diabetes Screening include:<ref name="pmid27979889">{{cite journal |vauthors= |title=2. Classification and Diagnosis of Diabetes |journal=Diabetes Care |volume=40 |issue=Suppl 1 |pages=S11–S24 |year=2017 |pmid=27979889 |doi=10.2337/dc17-S005 |url=}}</ref><ref name="pmid19502545">{{cite journal |vauthors= |title=International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes |journal=Diabetes Care |volume=32 |issue=7 |pages=1327–34 |year=2009 |pmid=19502545 |pmc=2699715 |doi=10.2337/dc09-9033 |url=}}</ref><ref name="pmid24126648">{{cite journal |vauthors=Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C |title=Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis |journal=Ann. Intern. Med. |volume=159 |issue=8 |pages=543–51 |year=2013 |pmid=24126648 |doi=10.7326/0003-4819-159-8-201310150-00007 |url=}}</ref><ref name="pmid22683134">{{cite journal |vauthors=Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE |title=Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study |journal=Lancet |volume=379 |issue=9833 |pages=2243–51 |year=2012 |pmid=22683134 |pmc=3555407 |doi=10.1016/S0140-6736(12)60525-X |url=}}</ref>
|[[Cortisol]]
* The general population should be screened every 3 years, beginning at age 45 (especially if their [[BMI]]>25kg/m2).
| rowspan="2" |[[Corticosteroids]]
* Younger individuals should be screened if they have [[BMI]]>25kg/m2 and at least one of the following risk factors:
|-
** Sedentary life style
|[[11β-hydroxylase deficiency]]
** 1st degree relative with DM
|Mutations in the [[CYP11B1]] gene
** African American, Native American, Latino, Asian American, Pacific Islander
|
** Low [[HDL-C]]
* [[Ambiguous genitalia]] in female
** History of [[Gestational diabetes|gestational DM]]
** [[Polycystic ovary syndrome]]
** Vascular disease


To test for type 2 diabetes, [[fasting plasma glucose]], 2-h plasma glucose after 75-g oral glucose tolerance test, and [[HbA1C]] are equally appropriate.
* [[Hypertension]] and [[hypokalemia]]
===Gestational diabetes===
* [[Virilization]]
All pregnant women should be screened for gestational diabetes in 24-28 weeks with 50 gram glucose test. Measurements greater than 130 mg/dL are considered positive and should proceed to 100 gram glucose test for diagnosis. High risk mothers should be screened as early as the first prenatal visit. These risk factors include:<ref name="pmid26696675">{{cite journal |vauthors= |title=2. Classification and Diagnosis of Diabetes |journal=Diabetes Care |volume=39 Suppl 1 |issue= |pages=S13–22 |year=2016 |pmid=26696675 |doi=10.2337/dc16-S005 |url=}}</ref><ref name="pmid24424622">{{cite journal |vauthors=Moyer VA |title=Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force recommendation statement |journal=Ann. Intern. Med. |volume=160 |issue=6 |pages=414–20 |year=2014 |pmid=24424622 |doi=10.7326/M13-2905 |url=}}</ref>
|[[Cortisol]] ↓
* A [[Family history (medicine)|family history]] of diabetes especially in first degree relatives
|-
* Maternal age >25 yrs
|Apparent mineralocorticoid excess syndrome (AME)
* Certain ethnic groups (such as Native American, Hispanic-American, African-American,  South or East Asian, Pacific Islander)
|Genetic or acquired defect of 11-HSD gene
* [[Body mass index]] greater than 25 kg/m<sup>2</sup>
* [[Cortisone]] decreases and [[cortisol]] accumulates and binds to [[aldosterone]] receptors
* Gestational diabetes or impaired glucose tolerance test in previous pregnancies
|
* Previous delivery of a baby >9 pounds
* Severe juvenile [[hypertension]]
* Personal history of  [[impaired glucose tolerance]] or [[impared fasting glucose]] (pre-diabetes)
* [[Hypercalciuria]], [[nephrocalcinosis]], [[polyuria]] (due to [[hypokalemia]]-induced [[nephrogenic diabetes insipidus]])
* [[Glycosuria]] at the first prenatal visit
* [[Renal failure]]
* Certain medical conditions (such as [[metabolic syndrome]], [[polycystic ovary syndrome]] (PCOS), current use of [[glucocorticoids]], [[hypertension]])
|[[Cortisol]] has [[mineralocorticoid]] effects
* Previous history of unexplained [[miscarriage (patient information)|miscarriage]] or [[stillbirth]]
|↓
* Smoking doubles the risk of gestational diabetes
|↓
* [[Multiple gestation]]
|Urinary free [[cortisone]] ↓↓
* Genetic predisposition (.e.g. glucokinase mutation)
|[[Dexamethasone]] and/or [[mineralocorticoid]] blockers
|-
|[[Liddle's syndrome|Liddle’s syndrome]] (Pseudohyperaldosteronism type 1)
|Mutation of the epithelial [[sodium]] channels ([[ENaC]]) [[gene]] in the distal [[renal tubules]]
|
* [[Hypertension]]


==Diagnosis==
* [[Hypokalemia]]
===Diabetes mellitus type 1 and type 2===
|No extra [[mineralocorticoid]] presents, and mutations in [[Sodium|Na]] channels mimic [[aldosterone]] mechanism
A [[fasting plasma glucose]] (FPG) <5.6 mmol/L (100 mg/dL), a [[plasma glucose]] <140 mg/dL (11.1 mmol/L) following an [[Oral glucose tolerance test|oral glucose challenge]] and an [[HbA1c]] <5.7% are considered normal.<br>
|↓
Diagnostic criteria for DM are:
|↓
*Symptoms of diabetes plus random blood glucose concentration ≥11.1 mmol/L (200 mg/dL)<sup>†</sup> '''OR'''
|[[Cortisol]]
*[[Fasting plasma glucose]] ≥7.0 mmol/L (126 mg/dL)<sup>‡</sup> '''OR'''
|[[Amiloride]] or [[triamterene]]
*[[Hemoglobin A1c]] ≥ 6.5% '''OR'''
|-
*2-h [[plasma glucose]] ≥11.1 mmol/L (200 mg/dL) during an [[oral glucose tolerance test]]<sup>¶</sup>
|[[Cushing’s syndrome]]
<br>Note:<br>
|
<small>
* The main pathogenetic mechanism is linked to the excess
†:Random is defined as without regard to time since the last meal.
of [[cortisol]] which saturates 11-HSD2 activity,
* This allows [[cortisol]] to bind [[mineralocorticoid receptor]]
|Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
* Proximal [[muscle weakness]]
* A [[round face]] often referred to as a "[[moon face]]"
* Excess [[sweating]]
* [[Headache]]
|[[Cortisol]] has [[mineralocorticoid]] effects
|↓
|
* ↓ if excess [[cortisol]] saturates 11-HSD2 enzyme activity


‡:Fasting is defined as no caloric intake for at least 8 h.
* ↑ in direct activation of [[renin]] [[angiotensin]] system activation by [[glucocorticoids]]
|Urinary free [[cortisol]] markedly ↑↑
|
* [[Pasireotide]], [[Cabergoline]], [[Ketoconazole]], and [[Metyrapone]]


¶:The test should be performed using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water, not recommended for routine clinical use.
* Adrenalectomy
</small>
|-
==== American Diabetes Association Diabetes Diagnostic Criteria 2017 (DO NOT EDIT)<ref name="pmid27979887">{{cite journal |vauthors= |title=Standards of Medical Care in Diabetes-2017: Summary of Revisions |journal=Diabetes Care |volume=40 |issue=Suppl 1 |pages=S4–S5 |year=2017 |pmid=27979887 |doi=10.2337/dc17-S003 |url=}}</ref>====
|Insensitivity to [[glucocorticoids]] (Chrousos syndrome)
|Mutations in [[glucocorticoid receptor]] (GR) gene
|
* [[Hypertension]]


{| align="center" style="border: 0px; font-size: 90%; margin: 3px;"
* Adrenal [[hyperandrogenism]]
! align="center" style="background:#DCDCDC;" |'''Criteria for the diagnosis of diabetes'''
|[[Deoxycorticosterone]] ([[Deoxycorticosterone|DOC]])
|↓
|↓
|[[Cortisol]]
|[[Dexamethasone]]
|-
|-
| align="left" style="background:#F5F5F5;" |[[Fasting plasma glucose|FPG]] ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.
|[[Cortisol]]-secreting adrenocortical [[carcinoma]]
|Multifactorial
|
Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
* Proximal [[muscle weakness]]
* A [[round face]] often referred to as a "[[moon face]]"
* Excess [[sweating]]
* [[Headache]]
|[[Cortisol]] has [[mineralocorticoid]] effects
|↓
|
* ↓ if excess [[cortisol]] saturates 11-HSD2 enzyme activity
 
* ↑ in direct activation of [[renin]] [[angiotensin]] system activation by [[glucocorticoids]]
|Urinary free [[cortisol]] markedly ↑↑
|[[Surgery]]
|-
|-
| align="center" style="background:#F5F5F5;" |'''OR'''
|Geller’s syndrome
|[[Mutation]] of [[mineralocorticoid]] (MR) receptor that alters its specificity and allows [[progesterone]] to bind MR
|Severe [[hypertension]] particularly during [[pregnancy]]
|[[Progesterone]] has [[mineralocorticoid]] effects
|↓
|↓
| -
|[[mineralocorticoid]] blockers
|-
|-
| align="left" style="background:#F5F5F5;" |2-h [[Blood glucose|Plasma Glucose]] (PG)  ≥200 mg/dL (11.1 mmol/L) during an [[Glucose tolerance test|OGTT]]. The test should be performed as described
|Gordon’s syndrome (Pseudohypoaldosteronism type 2)
by the [[WHO]], using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.
|Mutations of at least four genes have been identified, including WNK1 and WNK4
|
* [[Hypertension]]
 
* [[Hyperkalemia]]
 
* Normal renal function
|No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule
|↓
|Normal
|Hyperkalemia
|thiazide diuretics and/or dietary sodium restriction
|-
|-
| align="center" style="background:#F5F5F5;" |'''OR'''
| rowspan="4" |Exogenous causes
|Corticosteroids with mineralocorticoid activity
|Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone,
|
* [[Hypertension]]
 
* [[Hypokalemia]]
|Medications such as fludrocortisone
|↓
|↓
| -
|Change the treatment
|-
|-
| align="left" style="background:#F5F5F5;" |[[A1C]] ≥6.5% (48 mmol/mol).
|Licorice ingestion
|[[Glycyrrhetinic acid]] that binds [[mineralocorticoid]] receptor and blocks 11-HSD2 at the level of classical target tissues of [[aldosterone]]
|
* [[Hypertension]]
 
* [[Hypokalemia]]
|<nowiki>-</nowiki>
|↓
|↓
|Urinary free cortisol Moderate ↑
|Discontinue licorice
|-
|-
| align="center" style="background:#F5F5F5;" |'''OR'''
|Grapefruit
|High assumption of naringenin, a component of grapefruit, can also block 11-HSD
|
* [[Hypertension]]
| -
|↓
|↓
| -
|Discontinue grapefruit
|-
|-
| align="left" style="background:#F5F5F5;" |In a patient with classic symptoms of [[hyperglycemia]] or [[hyperglycemic]] crisis, a random [[plasma glucose]] ≥200 mg/dL (11.1 mmol/L).
|[[Estrogens]]
|[[Estrogens]] can retain [[sodium]] and water by different mechanisms, causing:
* Increased blood pressure values and suppressing the [[renin]] [[aldosterone]] system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of [[angiotensinogen]]
|
* [[Hypertension]]
 
* [[Headache]]
* [[Edema]]
* [[Weight gain]]
|<nowiki>-</nowiki>
|↓
|↓
| -
|Discontinue [[estrogens]]
|}
|}


===Gestational diabetes===
==== CAH must be differentiated from other causes of irregular menses and [[hirsutism]]: ====
There are 2 strategies to confirm the GDM diagnosis.
{| class="wikitable"
*'''One-step''' 75-g Oral glucose tolerance test (OGTT)
!Disease
::::::'''OR'''
!Differentiating Features
*'''Two-step''' approach with a 50-g (nonfasting) ''screen'' followed by a 100-g OGTT for those who screen positive.<ref name="pmid26807004">{{cite journal |vauthors= |title=Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers |journal=Clin Diabetes |volume=34 |issue=1 |pages=3–21 |year=2016 |pmid=26807004 |doi=10.2337/diaclin.34.1.3 |url=}}</ref>
|-
===One Step Strategy====
|[[Pregnancy]]
Perform a 75 g glucose tolerance test in 24-28 weeks of pregnancy and read the measures 1 h and 2 h after glucose ingestion as well as fasting glucose.<ref name="pmid26807004">{{cite journal |vauthors= |title=Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers |journal=Clin Diabetes |volume=34 |issue=1 |pages=3–21 |year=2016 |pmid=26807004 |doi=10.2337/diaclin.34.1.3 |url=}}</ref>
|
The OGTT should be performed in the morning after an overnight fast of at least 8 h.
* Pregnancy always should be excluded in a patient with a history of [[amenorrhea]]
The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded:
* Fasting: 92 mg/dL (5.1 mmol/L)
* 1 h: 180 mg/dL (10.0 mmol/L)
* 2 h: 153 mg/dL (8.5 mmol/L)
====Two Step Strategy====
In this approach, screening with a 1 h 50-g glucose load test (GLT) followed by a 3 h 100-g OGTT for those who screen positive.<ref name="pmid26696673">{{cite journal |vauthors= |title=Professional Practice Committee for the Standards of Medical Care in Diabetes-2016 |journal=Diabetes Care |volume=39 Suppl 1 |issue= |pages=S107–8 |year=2016 |pmid=26696673 |doi=10.2337/dc16-S018 |url=}}</ref>


The diagnosis of GDM is made when at least 2 out of 4 measures of 3 h 100-g OGTT became abnormal.
* Features include amenorrhea or [[oligomenorrhea]], abnormal [[uterine bleeding]], [[Nausea and vomiting|nausea/vomiting]], cravings, [[weight gain]] (although not in the early stages and not if vomiting), [[polyuria]], [[abdominal cramps]] and [[constipation]], [[fatigue]], [[dizziness]]/[[lightheadedness]], and [[Hyperpigmentation|increased pigmentation]] (moles, [[nipples]])


*The following table summarizes the diagnostic approach for gestational diabetes.
* [[Uterus|Uterine]] enlargement is detectable on [[abdominal examination]] at approximately 14 weeks of [[gestation]]


{| class="wikitable"
* [[Ectopic pregnancy]] may cause oligomenorrhea, amenorrhea, or abnormal uterine bleeding with [[abdominal pain]] and sometimes subtle or absent physical symptoms and signs of [[pregnancy]]
! rowspan="2" |
|-
! colspan="4" |Cut off (mg/dl)
|Hypothalamic amenorrhea
|
* Diagnosis of exclusion
* Seen in athletes, people on crash diets, patients with significant systemic illness, and those experiencing undue [[stress]] or [[anxiety]]
* Predisposing features are as follows [[weight loss]], particularly if features of [[anorexia nervosa]] are present or the [[BMI]] is <19 kg/m2
* Recent administration of depot [[Medroxyprogesterone acetate|medroxyprogesterone]], which may suppress [[ovarian]] activity for 6 months to a year
* Use of [[dopamine agonists]] (eg, antidepressants) and major [[tranquilizers]]
* [[Hyperthyroidism]]
* In patients with weight loss related to anorexia nervosa, fine hair growth ([[lanugo]]) may occur all over the body, but it differs from [[hirsutism]] in its fineness and wide distribution
|-
|[[Primary amenorrhea]]
|
* Causes include [[reproductive system]] abnormalities, [[chromosomal]] abnormalities, or [[delayed puberty]]
* If [[secondary sexual characteristics]] are present, an [[anatomic]] abnormality (eg, [[imperforate hymen]], which is rare) should be considered
* If secondary sexual characteristics are absent, a chromosomal abnormality (eg, [[Turner syndrome]] ) or [[delayed puberty]] should be considered
|-
|[[Cushing's syndrome|Cushing syndrome]]
|
* [[Cushing syndrome]] is due to excessive [[glucocorticoid]] secretion from the [[adrenal glands]], either primarily or secondary to stimulation from [[Pituitary gland|pituitary]] or ectopic hormones; can also be caused by exogenous [[steroid]] use
 
* Features include [[hypertension]], [[weight gain]] (central distribution), [[acne]], and abdominal striae Patients have [[Hyponatremia|low plasma sodium levels]] and elevated plasma cortisol levels on [[dexamethasone]] suppression testing
|-
|-
!Fasting
|[[Hyperprolactinemia]]
!1 Hour
|
!2 Hour
* Mild [[hyperprolactinemia]] may occur as part of [[PCOS]]-related hormonal dysfunction
!3 Hour
 
* Other causes include [[stress]], [[lactation]], and use of [[dopamine antagonists]]
* A [[prolactinoma]] of the [[pituitary gland]] is an uncommon cause and should be suspected if [[prolactin]] levels are very high (>200 ng/mL)
* Physical examination findings are usually normal
* As in patients with PCOS, hyperprolactinemia may be associated with mild [[galactorrhea]] and [[oligomenorrhea]] or [[amenorrhea]]; however, galactorrhea also can occur with [[nipple]] stimulation and/or [[stress]] when prolactin levels are within normal ranges
* A large [[prolactinoma]] may cause [[headaches]] and [[visual field]] disturbance due to pressure on the [[optic chiasm]], classically a gradually increasing bi-temporal hemianopsia
|-
|-
|Ovarian or adrenal tumor
|
|
:One step test
* Benign [[Ovarian tumor|ovarian tumors]] and ovarian cancer are rare causes of excessive [[androgen]] secretion; [[adrenocortical]] [[tumors]] also can increase the production of [[sex hormones]]
:::2 hour 75 g glucose tolerance test
* [[Abdominal swelling]] or [[mass]], [[abdominal pain]] due to fluid leakage or [[torsion]], [[dyspareunia]], abdominal [[ascites]], and features of [[metastatic]] disease may be present
|92
* Features of androgenization include [[hirsutism]], [[weight gain]], [[oligomenorrhea]] or [[amenorrhea]], [[acne]], [[clitoral hypertrophy]], deepening of the voice, and high [[Androgen|serum androgen]] (eg, [[testosterone]], other androgens) levels
|180
* In patients with an androgen-secreting tumor, serum testosterone is not suppressed by [[dexamethasone]]
|153
| ----
|-
|-
|[[Congenital adrenal hyperplasia]]
|
|
:Two step test
* Congenital adrenal hyperplasia is a rare [[genetic]] condition resulting from 21-hydroxylase deficiency
:::1 hour 50 g screening test
* The late-onset form presents at or around menarche Patients have features of androgenization and [[subfertility]]
| ----
* Affects approximately 1% of hirsute patients More common in Ashkenazi Jews (19%), inhabitants of the former Yugoslavia (12%), and Italians (6%)
|140
* Associated with high levels of [[17-hydroxyprogesterone]]
| ----
* A short [[adrenocorticotropic hormone]] stimulation test with measurement of serum17-hydroxyprogesterone confirms the diagnostic assays of a variety of androgenic hormones help define other rare adrenal enzyme deficiencies, which present similarly to [[21-hydroxylase deficiency]]
| ----
|-
|-
|Anabolic steroid abuse
|
|
:::3 hour 100 g test if screening test became positive
* [[Anabolic steroid|Anabolic steroids]] are synthetic hormones that imitate the actions of [[testosterone]] by increasing [[muscle]] bulk and strength
:::::Carpenter/Coustan approach<ref name="pmid7148898">{{cite journal |vauthors=Carpenter MW, Coustan DR |title=Criteria for screening tests for gestational diabetes |journal=Am. J. Obstet. Gynecol. |volume=144 |issue=7 |pages=768–73 |year=1982 |pmid=7148898 |doi= |url=}}</ref>
* Should be considered if the patient is a serious sportswoman or bodybuilder
|95
* Features include [[virilization]] (including [[acne]] and [[hirsutism]]), often increased muscle bulk in male pattern, [[oligomenorrhea]] or [[amenorrhea]], [[clitoromegaly]], [[gastritis]], [[hepatomegaly]], [[alopecia]], and aggression
|180
* Altered [[liver function test]] results are seen
|155
|140
|-
|-
|[[Hirsutism]]
|
|
:::::National Diabetes Data Group (NDDG) approach<ref name="pmid510803">{{cite journal |vauthors= |title=Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group |journal=Diabetes |volume=28 |issue=12 |pages=1039–57 |year=1979 |pmid=510803 |doi= |url=}}</ref>
* [[Hirsutism]] is excessive facial and body hair, usually coarse and in a male pattern of distribution
|105
* Approximately 10% of women report unwanted facial hair
|190
* There is often a family history and typically some Mediterranean or Middle Eastern ancestry
|165
* May also result from use of certain [[medications]], both [[androgens]], and others including [[danazol]], [[glucocorticoids]], [[cyclosporine]], and [[phenytoin]]
|145
* [[Menstrual cycle|Menstrual]] history is normal
* When the cause is [[Genetics|genetic]], the excessive hair, especially on the face (upper lip), is present throughout adulthood, and there is no virilization
* When secondary to medications, the excessive hair is of new onset, and other features of virilization, such as [[acne]] and deepened voice, may be present
|}
|}
==Prevention==
Life style modification is the mainstay of prevention of diabetes mellitus. It includes, changes in diet, weight reduction and exercise. The strongest evidence for diabetes prevention comes from the Diabetes Prevention Program (DPP). The DPP demonstrated that an intensive lifestyle intervention could reduce the incidence of type 2 diabetes by 58% over 3 years.<ref name="pmid17098085">{{cite journal |vauthors=Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J |title=Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study |journal=Lancet |volume=368 |issue=9548 |pages=1673–9 |year=2006 |pmid=17098085 |doi=10.1016/S0140-6736(06)69701-8 |url=}}</ref>


==References==
==References==
{{reflist|2}}
{{reflist|2}}

Latest revision as of 15:57, 23 April 2018

This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on 21-hydroxylase deficiency, 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency, cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia.

Adrenal insufficiency
Adrenal gland

Congenital adrenal hyperplasia main page

Overview

Classification

21-hydroxylase deficiency
11β-hydroxylase deficiency
17 alpha-hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Cytochrome P450-oxidoreductase (POR) deficiency (ORD)
Lipoid congenital adrenal hyperplasia

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Synonyms and keywords: Congenital adrenal hyperplasia; CAH; Adrenal hyperplasia.

Overview

Congenital adrenal hyperplasia consists of several disorders resulting from defective enzymes and proteins involved in steroid and cortisol synthesis pathways. Defects in steroid biosynthesis are caused by several genetic mutations and may lead to delayed puberty, precocious puberty or ambiguous genitalia in specific disorders. The decrease in cortisol level leads to the release of the inhibitory feedback on corticotropin (ACTH) production. The high ACTH level causes increase cortisol precursors and overproduction of other hormones. The most common cause of congenital adrenal hyperplasia is a 21-hydroxylase deficiency, which accounts for more than 95% of cases. Other causes include 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), and congenital lipoid adrenal hyperplasia.

Classification

Congenital adrenal hyperplasia (CAH) is classified into seven types based on the genetic causes that lead to hyperplasia and hormonal imbalance. CAH is hyperplasia of different layer of Adrenal cortex. Within the adrenal cortex, there are three layers named zones; each of them has a distinct cell type and secrete specific hormones.

Adrenal cortex zones based on the hormonal synthesis ability and location:

Adrenal cortex zones - By Jpogi - https://commons.wikimedia.org/wiki/File:Adrenal_gland_%28cortex%29.JPG, CC0, https://commons.wikimedia.org/w/index.php?curid=37838551

Impairment of each pathway and enzyme may lead to a specific subtype of congenital adrenal hyperplasia include:

Adrenal steroid synthesis pathways in adrenal cortex and related enzymes

Adrenal steroid synthesis pathways in adrenal cortex and related enzymes [1]

Summary and important Characteristics of the different congenital adrenal hyperplasia subtypes: [2][3][4]

Disease History and symptoms Laboratory findings Defective gene
Blood pressure Genitalia Cortisol Aldosterone Androgens Estrogens Increased hormone precursors Potassium levels
21-hydroxylase deficiency Classic type, salt-wasting ↓↓ Relatively low

CYP21A1 and CYP21A2 gene

Classic type, non-salt-wasting Normal
  • Male: normal or scrotal pigmentation and large phallus
Relatively low Normal CYP21A1 and CYP21A2 gene
Non-classic type Normal Normal Normal Relatively low Normal

CYP21A1 and CYP21A2 gene

17-α hydroxylase deficiency Normal corticosterone

Normal cortisol

CYP17A1
11-β hydroxylase deficiency
  • Male: Normal or scrotal pigmentation and large phallus
Relatively low CYP11B1
3 beta-hydroxysteroid dehydrogenase deficiency Male:↓

Female:↑

HSD3B2
Cytochrome P450-oxidoreductase (POR) deficiency (ORD) Normal Normal Normal Mutations in the flavoprotein co-factor of the enzymes CYP17A1, CYP21A2, and CYP19A1 (aromatase).
Congenital lipoid adrenal hyperplasia None of precursors increased Gene mutations on chromosome 8, codes for a protein called steroid acute regulatory protein (StAR)

Differential Diagnosis

Congenital adrenal hyperplasia can present with different symptoms such as:

Differential diagnosis for each of these symptoms are described in below tables.

Congenital adrenal hyperplasia must be differentiated from diseases that cause ambiguous genitalia:[5][6]

Disease Steroid status Important clinical findings
Increased Decreased
Classic type of 21-hydroxylase deficiency
11-β hydroxylase deficiency
17-α hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Gestational hyperandrogenism

Congenital adrenal hyperplasia must be differentiated from diseases that cause virilization and hirsutism in female:[7][6][8]

Disease Steroid status Other laboratory Important clinical findings
Non-classic type of 21-hydroxylase deficiency Increased:
  • No symptoms in infancy and male
11-β hydroxylase deficiency Increased:

Decreased:

3 beta-hydroxysteroid dehydrogenase deficiency Increased:

Decreased:

Polycystic ovary syndrome
Adrenal tumors
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Ovarian virilizing tumor
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Cushing's syndrome
Hyperprolactinemia

Some types of congenital adrenal hyperplasia must be differentiated from diseases with primary amenorrhea:[9][2][3][4][10][11][12][13]

Disease Cause Differentiating
Findings Uterus Breast development Testosterone LH FSH Karyotyping
3 beta-hydroxysteroid dehydrogenase deficiency

Yes in female

Yes in female

Normal

Normal

XY and XX

17-alpha-hydroxylase deficiency

No

No

Normal

Normal

XY

Gonadal dysgenesis
  • Mutations in SRY, FOG2/ZFPM2, and WNT1

Yes

Yes

XY

Testicular regression syndrome
  • Loss of testicular function and tissue early in development

No

No

XY

LH receptor defects

No

No

XY

5-alpha-reductase type 2 deficiency

No

No

Normal male range

High to normal

High to normal

XY

Androgen insensitivity syndrome 

No

Yes

Normal male range

Normal

Normal

XY

Mullerian agenesis

No

Yes

Normal female range

Normal

Normal

XX

Primary ovarian insufficiency

Yes

Yes

Normal female range

XX

Hypogonadotropic hypogonadism
  • Functional, sellar masses

Yes

No

Normal female range

Low

Normal

XX

Turner syndrome

  • Chromosomal

Yes

Yes

Normal female range

45 XO

17 alpha-hydroxylase deficiency and 11β-hydroxylase deficiency can cause low reninemic hypertension and should be differentiate from other causes of pseudohyperaldosteronism (low renin):

Pseudohyperaldosteronism causes Disease Etiology Clinical features Labratory Treatment
Elevated mineralocorticoid Renin Aldosterone Other
Endogenous causes 17 alpha-hydroxylase deficiency Mutations in the CYP17A1 gene Deoxycorticosterone (DOC) Cortisol Corticosteroids
11β-hydroxylase deficiency Mutations in the CYP11B1 gene Cortisol
Apparent mineralocorticoid excess syndrome (AME) Genetic or acquired defect of 11-HSD gene Cortisol has mineralocorticoid effects Urinary free cortisone ↓↓ Dexamethasone and/or mineralocorticoid blockers
Liddle’s syndrome (Pseudohyperaldosteronism type 1) Mutation of the epithelial sodium channels (ENaC) gene in the distal renal tubules No extra mineralocorticoid presents, and mutations in Na channels mimic aldosterone mechanism Cortisol Amiloride or triamterene
Cushing’s syndrome
  • The main pathogenetic mechanism is linked to the excess

of cortisol which saturates 11-HSD2 activity,

Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity) Cortisol has mineralocorticoid effects
  • ↓ if excess cortisol saturates 11-HSD2 enzyme activity
Urinary free cortisol markedly ↑↑
  • Adrenalectomy
Insensitivity to glucocorticoids (Chrousos syndrome) Mutations in glucocorticoid receptor (GR) gene Deoxycorticosterone (DOC) Cortisol Dexamethasone
Cortisol-secreting adrenocortical carcinoma Multifactorial

Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)

Cortisol has mineralocorticoid effects
  • ↓ if excess cortisol saturates 11-HSD2 enzyme activity
Urinary free cortisol markedly ↑↑ Surgery
Geller’s syndrome Mutation of mineralocorticoid (MR) receptor that alters its specificity and allows progesterone to bind MR Severe hypertension particularly during pregnancy Progesterone has mineralocorticoid effects - mineralocorticoid blockers
Gordon’s syndrome (Pseudohypoaldosteronism type 2) Mutations of at least four genes have been identified, including WNK1 and WNK4
  • Normal renal function
No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule Normal Hyperkalemia thiazide diuretics and/or dietary sodium restriction
Exogenous causes Corticosteroids with mineralocorticoid activity Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone, Medications such as fludrocortisone - Change the treatment
Licorice ingestion Glycyrrhetinic acid that binds mineralocorticoid receptor and blocks 11-HSD2 at the level of classical target tissues of aldosterone - Urinary free cortisol Moderate ↑ Discontinue licorice
Grapefruit High assumption of naringenin, a component of grapefruit, can also block 11-HSD - - Discontinue grapefruit
Estrogens Estrogens can retain sodium and water by different mechanisms, causing:
  • Increased blood pressure values and suppressing the renin aldosterone system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of angiotensinogen
- - Discontinue estrogens

CAH must be differentiated from other causes of irregular menses and hirsutism:

Disease Differentiating Features
Pregnancy
  • Pregnancy always should be excluded in a patient with a history of amenorrhea
Hypothalamic amenorrhea
  • Diagnosis of exclusion
  • Seen in athletes, people on crash diets, patients with significant systemic illness, and those experiencing undue stress or anxiety
  • Predisposing features are as follows weight loss, particularly if features of anorexia nervosa are present or the BMI is <19 kg/m2
  • Recent administration of depot medroxyprogesterone, which may suppress ovarian activity for 6 months to a year
  • Use of dopamine agonists (eg, antidepressants) and major tranquilizers
  • Hyperthyroidism
  • In patients with weight loss related to anorexia nervosa, fine hair growth (lanugo) may occur all over the body, but it differs from hirsutism in its fineness and wide distribution
Primary amenorrhea
Cushing syndrome
Hyperprolactinemia
Ovarian or adrenal tumor
Congenital adrenal hyperplasia
  • Congenital adrenal hyperplasia is a rare genetic condition resulting from 21-hydroxylase deficiency
  • The late-onset form presents at or around menarche Patients have features of androgenization and subfertility
  • Affects approximately 1% of hirsute patients More common in Ashkenazi Jews (19%), inhabitants of the former Yugoslavia (12%), and Italians (6%)
  • Associated with high levels of 17-hydroxyprogesterone
  • A short adrenocorticotropic hormone stimulation test with measurement of serum17-hydroxyprogesterone confirms the diagnostic assays of a variety of androgenic hormones help define other rare adrenal enzyme deficiencies, which present similarly to 21-hydroxylase deficiency
Anabolic steroid abuse
Hirsutism
  • Hirsutism is excessive facial and body hair, usually coarse and in a male pattern of distribution
  • Approximately 10% of women report unwanted facial hair
  • There is often a family history and typically some Mediterranean or Middle Eastern ancestry
  • May also result from use of certain medications, both androgens, and others including danazol, glucocorticoids, cyclosporine, and phenytoin
  • Menstrual history is normal
  • When the cause is genetic, the excessive hair, especially on the face (upper lip), is present throughout adulthood, and there is no virilization
  • When secondary to medications, the excessive hair is of new onset, and other features of virilization, such as acne and deepened voice, may be present

References

  1. "File:Adrenal Steroids Pathways.svg - Wikimedia Commons".
  2. 2.0 2.1 Moreira AC, Leal AM, Castro M (1990). "Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency". J. Clin. Endocrinol. Metab. 71 (1): 86–91. doi:10.1210/jcem-71-1-86. PMID 2164530.
  3. 3.0 3.1 Heremans GF, Moolenaar AJ, van Gelderen HH (1976). "Female phenotype in a male child due to 17-alpha-hydroxylase deficiency". Arch. Dis. Child. 51 (9): 721–3. PMC 1546244. PMID 999330.
  4. 4.0 4.1 Biglieri EG (1979). "Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome". J. Steroid Biochem. 11 (1B): 653–7. PMID 226795.
  5. Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
  6. 6.0 6.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
  7. Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
  8. Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=
  9. Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C (2011). "Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients". J. Clin. Endocrinol. Metab. 96 (2): 296–307. doi:10.1210/jc.2010-1024. PMID 21147889.
  10. Saenger P (1996). "Turner's syndrome". N. Engl. J. Med. 335 (23): 1749–54. doi:10.1056/NEJM199612053352307. PMID 8929268.
  11. Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R (2015). "Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis". Fertil. Steril. 103 (5): 1297–304. doi:10.1016/j.fertnstert.2015.01.043. PMID 25813279.
  12. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. PMID 4432067.
  13. Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.